Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
In this study, an investigational medication named BXCL501 is being tested for the treatment
of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia,
schizoaffective and schizophreniform disorder. This study compares the study drug to a
placebo.